Dako Sponsors Largest Histology Congress for 34th Year in a Row

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, is a sponsor of this year’s National Society for Histotechnology (NSH) Symposium.

The 2014 annual meeting for NSH members is being held Aug. 22-27 at the Austin Convention Center in Austin, Texas, where the company will demonstrate a wide range of its pathology and genomics solutions.

Symposium attendees will be able to see live demonstrations of Agilent’s newest pathology solution, Dako Omnis, at Booth 301. Dako Omnis automates both IHC and ISH processes, allowing entire patient cases to be processed simultaneously; this in turn enables results for both IHC and ISH to be delivered at the same time, a breakthrough for pathology labs. A fully automated fluorescent ISH (FISH) solution will also be introduced for use with commercially available FISH probes and the IQFISH fast hybridization buffer, thus enabling an efficient, flexible and high-quality FISH workflow on the Dako Omnis platform.

Agilent will also showcase its complete pathology and genomics solutions, including NGS, IHC, ISH, histostaining and connectivity. Attendees can visit a fluorescence microscopy room to see some of the latest technologies, such as the Agilent high resolution SureFISH probes, the Dako quality reagents and pharmDx(tm) kits, including HER2 IQFISH pharmDx™. Agilent’s booth will offer information on the company’s next-generation sequencing (NGS) solution, with the industry-leading HaloPlex and SureSelect products for target enrichment, as well as an introduction to Agilent’s Bravo Automated Liquid Handling platform. The platform enables automation of a wide range of critical genomics applications for research - including NGS sample preparation - providing significantly greater reproducibility and throughput than can be achieved through manual methods.

“Being a part of the NSH is extremely important to us,” said Britt Meelby Jensen, vice president of Marketing and Pathology Sales in Agilent’s Diagnostics and Genomics business. “It is so valuable to meet the delegates and show them the value Agilent can bring to their laboratory. We offer the widest portfolio of solutions, spanning the entire clinical continuum from discovery research to clinical diagnostics.”

Attendees at NSH are members of the histology profession and other key decision-makers in the field of pathology, primarily within the United States.

Agilent Technologies Inc. (NYSE: A) is a leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Agilent acquired Dako in 2012, a well-known provider of reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Information about Agilent is available at www.agilent.com and information about Dako products is available at www.dako.com.

In September 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. On Aug. 1, 2014, the company’s electronic measurement business began operating as Keysight Technologies, Inc., a wholly owned subsidiary. The separation is expected to be completed in early November 2014.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the separation of Agilent’s electronic measurement business; future revenues, earnings and profitability; the future demand for the company’s products and services; and customer expectations. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.

In addition, other risks that Agilent faces include those detailed in Agilent’s filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information.

# # #